Qi Chen

机构：Institute of Electronics, Chenguang Research Institute of Chemical Industry, Zhongshan Hospital of Xiamen University, Nanjing University · ORCID：0000-0002-6568-7267

发表论文 71 篇 · 总被引 4586 次 · h-index 23

代表论文

• Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials (2022 · The Lancet Respiratory Medicine · 被引 145)
• Rational development of multicomponent mRNA vaccine candidates against mpox (2023 · Emerging Microbes & Infections · 被引 91)
• Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models (2022 · Cell Discovery · 被引 51)
• Oncolytic Zika Virus: New Option for Glioblastoma Treatment (2022 · DNA and Cell Biology · 被引 20)
• A pangolin-origin SARS-CoV-2-related coronavirus: infectivity, pathogenicity, and cross-protection by preexisting immunity (2023 · Cell Discovery · 被引 17)
• Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial (2023 · The Lancet Regional Health - Western Pacific · 被引 13)